| __timestamp | Biogen Inc. | Corcept Therapeutics Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 2232342000 | 34916000 |
| Thursday, January 1, 2015 | 2113100000 | 36949000 |
| Friday, January 1, 2016 | 1947900000 | 45240000 |
| Sunday, January 1, 2017 | 1935500000 | 62416000 |
| Monday, January 1, 2018 | 2106300000 | 81289000 |
| Tuesday, January 1, 2019 | 2374700000 | 100359000 |
| Wednesday, January 1, 2020 | 2504500000 | 105326000 |
| Friday, January 1, 2021 | 2674300000 | 122356000 |
| Saturday, January 1, 2022 | 2403600000 | 152848000 |
| Sunday, January 1, 2023 | 2549700000 | 184259000 |
| Monday, January 1, 2024 | 2403700000 |
In pursuit of knowledge
In the competitive world of biotechnology, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Biogen Inc. and Corcept Therapeutics Incorporated from 2014 to 2023. Over this period, Biogen's SG&A expenses have shown a steady increase, peaking in 2021 with a 38% rise from 2014. Meanwhile, Corcept Therapeutics has experienced a remarkable surge, with expenses growing over 400% in the same timeframe. This stark contrast highlights the differing strategies and growth trajectories of these two companies. While Biogen's expenses reflect its established market presence, Corcept's rapid increase underscores its aggressive expansion efforts. Understanding these trends provides valuable insights into the financial strategies of leading biotech firms, offering a window into their operational priorities and market positioning.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Corcept Therapeutics Incorporated
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Biogen Inc.
SG&A Efficiency Analysis: Comparing Novartis AG and Biogen Inc.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Biogen Inc.
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Research and Development Investment: Biogen Inc. vs Corcept Therapeutics Incorporated
Biogen Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
Biogen Inc. and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Comparing SG&A Expenses: Bio-Techne Corporation vs Corcept Therapeutics Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs ACADIA Pharmaceuticals Inc. Trends and Insights